Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 12/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576006 | 0.93 | PTGER4 (0.50) | PTGER4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14576934 | 0.90 | PTGER4 (0.39) | PTGER4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12284289 | 0.89 | PTGER4 (0.35) | PTGER4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14576018 | 0.89 | SMN1; SMN2 (0.43) | PTGER4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14576141 | 0.88 | IKBKB (0.40) | PTGER4SMN1; SMN2 | |
| SCHEMBL2552453 | 0.87 | USP2 (0.40) | PTGER4KDM4EALDH1A1HPGDGAA | |
| SCHEMBL2552155 | 0.87 | PTGER4 (0.47) | PTGER4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2555588 | 0.86 | HPGD (0.49) | PTGER4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2550896 | 0.85 | PTGER4 (0.51) | PTGER4RIPK2 | |
| SCHEMBL14642705 | 0.85 | RIPK2 (0.51) | PTGER4KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | claimed |
| EP-2552208-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| WO-2011123609-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | PTGER4 3190/4885KDM4E 764/4885ALDH1A1 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.